Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.63% | |
Lower Bollinger Band Touch | Weakness | 0.63% | |
Lower Bollinger Band Walk | Weakness | 3.88% | |
Below Lower BB | Weakness | 3.88% | |
Lower Bollinger Band Touch | Weakness | 3.88% | |
20 DMA Resistance | Bearish | 2.31% | |
50 DMA Resistance | Bearish | 2.31% | |
Wide Range Bar | Range Expansion | 2.31% | |
Lower Bollinger Band Walk | Weakness | 2.31% |
Alert | Time |
---|---|
Down 1% | about 20 hours ago |
Up 2% | about 20 hours ago |
Up 1% | about 20 hours ago |
Rose Above Previous Day's High | 1 day ago |
Up 5% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/01/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Cancer Center Her2/Neu
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.44 |
52 Week Low | 8.0 |
Average Volume | 28,302 |
200-Day Moving Average | 14.44 |
50-Day Moving Average | 13.87 |
20-Day Moving Average | 13.55 |
10-Day Moving Average | 13.33 |
Average True Range | 0.87 |
RSI (14) | 43.50 |
ADX | 14.16 |
+DI | 13.88 |
-DI | 19.66 |
Chandelier Exit (Long, 3 ATRs) | 12.19 |
Chandelier Exit (Short, 3 ATRs) | 14.49 |
Upper Bollinger Bands | 14.71 |
Lower Bollinger Band | 12.38 |
Percent B (%b) | 0.2 |
BandWidth | 17.17 |
MACD Line | -0.28 |
MACD Signal Line | -0.16 |
MACD Histogram | -0.1162 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.99 | ||||
Resistance 3 (R3) | 14.05 | 13.72 | 13.80 | ||
Resistance 2 (R2) | 13.72 | 13.43 | 13.70 | 13.74 | |
Resistance 1 (R1) | 13.29 | 13.25 | 13.51 | 13.23 | 13.67 |
Pivot Point | 12.96 | 12.96 | 13.07 | 12.94 | 12.96 |
Support 1 (S1) | 12.53 | 12.67 | 12.75 | 12.47 | 12.03 |
Support 2 (S2) | 12.20 | 12.49 | 12.18 | 11.96 | |
Support 3 (S3) | 11.77 | 12.20 | 11.90 | ||
Support 4 (S4) | 11.71 |